Tamtam Try Tamtam free
Chiesi Group logo

Chiesi Group account plan

Biopharma, BCorp, Global, Research

At a glance

Chiesi Group is a family-owned Parma pharmaceutical group in respiratory, rare diseases and specialty care, with FY2025 revenues of €3,625M.

Chiesi Group is a family-owned, research-focused pharmaceutical group founded in 1935 and headquartered in Parma, Italy, controlled through Valline S.r.l. It develops and sells medicines in three business areas: Air (respiratory), Rare (rare and ultra-rare diseases) and Care (neonatology, transplant, cardiovascular and consumer healthcare), through 31 affiliates, 4 production plants and 7 R&D centres. FY2025 consolidated revenues were €3,625M (+8.2% at constant exchange rates), with EBITDA of €931M (25.7% of revenues) and record R&D investment of €885M. The group had 7,934 employees at end-2025 and is a Benefit Corporation and certified B Corp; Jean-Marc Bellemin is CFO and Interim Group CEO.

Business units

Strategic priorities

€6 billion of sales by 2030
Chiesi aims to reach €6 billion of sales by 2030, with around 10-15% of the goal from acquisitions in respiratory, specialty pharma and rare diseases.
Grow rare diseases and the U.S.
Rare diseases and the United States drive growth: the U.S. grew 28.9% at CER in 2025 and 9.6% @CER in H1 2026.
Carbon Minimal Inhaler rollout
Move six pMDI formulations to the low-GWP, non-PFAS propellant HFA 152a, cutting product footprint by up to 90%, with a Bespak partnership to deliver CMIs at scale.
Climate targets
SBTi targets of a 90% cut in Scope 1 and 2 emissions by 2030 and a 90% cut in key Scope 3 categories by 2035, both against 2019.
Mid-single-digit growth in 2026
The 2026 outlook is mid-single-digit revenue growth, with late-stage respiratory programmes and low-GWP propellant pMDI launches.

Latest results

In H1 2026 (six months to 30 June) revenues were €1.89 billion, up 3.6% at constant exchange rates excluding the KalVista acquisition, slower than the 8.2% growth of FY2025. Rare diseases grew 9.9% @CER, neonatology and specialty care 6.5% and respiratory was broadly stable at -0.8%. By region the United States grew 9.6% @CER, Europe 0.9% and remaining geographies 5.5%. The EBITDA margin was 29.4% and R&D investment €426 million, about 22.5% of revenues.

Investments and deals

KalVista Pharmaceuticals acquisition
Completed in H1 2026, adding an oral on-demand treatment for hereditary angioedema and expanding the U.S. presence.
Nerviano site
Industrial site near Milan acquired in March 2025 and being redeveloped for sterile biologics and carbon-minimal inhalers.
Biotech Center of Excellence in Parma
A €400M investment inaugurated in 2024, integrating the full biologics production process.
Rare disease partnerships
Three 2025 partnerships with Key2Brain, Arbor Biotechnologies and Aliada Therapeutics on brain-penetrating enzyme therapies and gene editing.
Record R&D
R&D investment of €885M in FY2025, 24.4% of revenues.

Challenges and risks

Slowing growth and flat Europe
H1 2026 growth slowed to 3.6% @CER, with Europe at +0.9% and EU Top5 markets broadly stable in 2025.
Generics on legacy respiratory products
Continued generic competition on legacy respiratory products is offset only by growth of the triple inhaled therapy.
Inhaler propellant regulation
Regulatory pressure on high-GWP inhaler propellants and a market shift to dry powder and soft mist inhalers are the key climate risk.
Supply chain dependence
Dependence on direct suppliers and external manufacturers can cause shortages, delays and quality issues affecting critical therapies.
CEO transition and U.S. tariffs
CEO Giuseppe Accogli left on 15 May 2026 and a permanent successor is being sought; U.S. tariffs may eventually require U.S. manufacturing.

What leadership says

“the acquisition of KalVista further strengthens our position in rare diseases and expands our presence in the U.S.”

Jean Marc Bellemin, CFO and Interim CEO · H1 2026 results release, 9 September 2026

“We are looking in respiratory, in specialty pharma and in rare diseases, not only in Italy, but also globally.”

Giuseppe Accogli, Group CEO (until May 2026) · Reuters interview, 5 June 2025

“reflect the resilience of our strategy and the strength of our global footprint”

Jean Marc Bellemin, CFO and Interim CEO · H1 2026 results release, 9 September 2026

Where a supplier can help

Inhaler manufacturing and propellant transition
The Carbon Minimal Inhaler rollout and Nerviano redevelopment need device, filling-line and engineering suppliers.
U.S. rare disease commercial build-out
U.S. growth and the KalVista integration call for patient support, market access and CRM providers in rare diseases.
Supply chain resilience
Supply chain dependence on external manufacturers creates demand for supplier risk monitoring, CMOs and inventory planning tools.
Emissions reduction across the value chain
The 2030 and 2035 SBTi targets push Chiesi to work with vendors on CO2 reduction, opening doors for energy, logistics and carbon accounting suppliers.
Clinical development support
Record R&D and late-stage respiratory programmes create demand for CROs and clinical data services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Chiesi Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Chiesi Group

What does Chiesi Group do?

Chiesi is a family-owned pharmaceutical group from Parma that develops and sells medicines for respiratory health, rare diseases and specialty care such as neonatology and transplant.

What is Chiesi's revenue?

FY2025 consolidated revenues were €3,625M, up 8.2% at constant exchange rates, with EBITDA of €931M. H1 2026 revenues were €1.89 billion.

How many employees does Chiesi have?

Chiesi had 7,934 employees at the end of 2025, after creating 392 new roles.

Who leads Chiesi Group?

Alessandro Chiesi is Chairperson. Jean-Marc Bellemin is Group CFO and Interim Group CEO since Giuseppe Accogli left on 15 May 2026.

What is Chiesi's strategy?

Chiesi aims to reach €6 billion of sales by 2030 through growth in rare diseases, the U.S. and acquisitions, while moving its inhalers to a low-GWP propellant.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)